Grant of Stock Options to Directors
First written in FY2017. 4 of 15 entries say "Advanced", first in FY2018-Q2. Latest entry: FY2025.
- FY2025Update on the vesting and expiration status of stock acquisition rightsAnnual report
「After vesting End of previous consolidated fiscal year 1,500 86,200 — — Vesting — — 86,200 — Exercise — — — — Expiration 600 — — — Outstanding 900 86,200 86,200 —」
The 86,200 shares underlying the Series 8 stock acquisition rights vested, and 600 shares underlying the Series 4 stock acquisition rights expired. The 750,000 shares underlying the Series 9 stock acquisition rights remain unvested. - FY2025-H1AdvancedAnnual report
「Series 9 stock acquisition rights Resolution date 26 December 2024 General Meeting of Shareholders Category and number of eligible grantees (people) Company directors 3 Company employees 1 Total 4 Number of stock acquisition rights (rights)* 7,500 Class, details and number of shares underlying the stock acquisition rights (shares)* Common shares 750,000 Exercise period for stock acquisition rights * From 31 January 2027 To 30 January 2035」
The Series 9 stock acquisition rights were issued on 17 February 2025, and 7,500 rights underlying 750,000 shares were granted to 3 directors and 1 employee. The exercise period runs from 31 January 2027 to 30 January 2035. - FY2024RaisedAnnual report
「At the 16th Annual General Meeting of Shareholders held on 26 December 2024, a resolution was passed, separately from director compensation, to set an annual limit of ¥350 million for stock options granted to the Company's directors, including outside directors but excluding directors who are Audit and Supervisory Committee members. The purpose is to increase their motivation and morale to enhance corporate and shareholder value and to promote management that is mindful of shareholders and the share price.」
The annual limit for stock options for directors was increased from the previous limit of ¥300 million to ¥350 million. In addition, 43,100 shares each underlying the Series 7 and Series 8 stock acquisition rights expired, leaving 86,200 unvested shares each. - FY2024-Q2Update to gain on reversal of stock acquisition rightsAnnual report
「Gain on reversal of stock acquisition rights ¥21.610 million ¥15.724 million」
During the current second quarter cumulative consolidated period, the Company recorded a gain on reversal of stock acquisition rights of ¥15.724 million as extraordinary income. - FY2024-Q1Update to gain on reversal of stock acquisition rightsAnnual report
「Gain on reversal of stock acquisition rights ¥21.302 million ¥15.724 million」
During the current first quarter cumulative consolidated period, the Company recorded a gain on reversal of stock acquisition rights of ¥15.724 million as extraordinary income. - FY2023Recognition of gain on reversal of stock acquisition rights due to expirationAnnual report
「Gain on reversal of stock acquisition rights ¥22.125 million」
During the consolidated fiscal year, the Company recorded a gain on reversal of stock acquisition rights of ¥22.125 million following their expiration due to non-exercise. For each of the Series 7 and Series 8 stock acquisition rights, 86,200 shares expired and 129,300 shares remained unvested. - FY2023-Q2Recognition of Gain on Reversal of Stock Acquisition RightsAnnual report
「Gain on reversal of stock acquisition rights ¥21.610 million」
During the current second quarter cumulative consolidated period, the Company recorded a gain on reversal of stock acquisition rights of ¥21.610 million as extraordinary income. - FY2023-Q1Recognition of Gain on Reversal of Stock Acquisition RightsAnnual report
「Gain on reversal of stock acquisition rights - ¥21.302 million」
During the current first quarter cumulative consolidated period, the Company recorded a gain on reversal of stock acquisition rights of ¥21.302 million as extraordinary income. - FY2021ReframedAnnual report
「The basic policy is to establish a compensation structure for the Company's directors, excluding directors who are Audit and Supervisory Committee members, that is linked to shareholder interests so that it functions fully as an incentive to achieve sustained growth in corporate value, and to set appropriate compensation levels based on each director's responsibilities when determining individual compensation.」
Disclosure has expanded from the previous disclosure of stock option grants for directors to a shareholder-interest-linked executive compensation policy covering fixed compensation, KPI-linked compensation and stock-based compensation. - FY2021-Q2AdvancedAnnual report
「The stock acquisition rights issued during the current second quarter accounting period are as follows. Series 7 stock acquisition rights: 2,155 rights, 215,500 common shares, and an exercise payment amount of ¥363 per share. Series 8 stock acquisition rights: 2,155 rights, 215,500 common shares, and an exercise payment amount of ¥363 per share.」
The Series 7 and Series 8 stock acquisition rights issued on 15 January 2021 were granted to 3 directors of the Company. The Series 8 rights are subject to conditions under which the exercisable percentage is 60%, 80% or 100%, depending on cumulative operating profit for the fiscal years ending September 2021 through September 2023. - FY2020RaisedAnnual report
「Separately from directors’ compensation, at the 11th annual general meeting of shareholders held on 24 December 2019, the Company resolved to grant stock options of up to ¥300,000 thousand annually to the Company’s directors, excluding outside directors and directors who are Audit and Supervisory Committee members, with the aim of increasing their motivation and morale to enhance corporate and shareholder value and promoting management that takes shareholders and the share price into account.」
The resolution states that the annual limit for stock options for directors will be increased from the previous limit of ¥50 million to ¥300 million. - FY2019AdvancedAnnual report
「Exercised: 160 Expired: - Balance not exercised: 5,600」
During the fiscal year, 160 shares underlying the third series of stock acquisition rights were exercised, leaving an unexercised balance of 5,600 shares at the end of the period. In addition, 5,200 shares underlying the fourth series expired, leaving an unvested balance of 16,900 shares. - FY2018Partial non-exercise due to failure to meet performance conditionsAnnual report
「Because the ordinary profit reported in the annual securities report for the fiscal year ending September 2018 is less than ¥572 million under (3)(i) above, the fifth and sixth series of stock acquisition rights will not be exercised.」
The grants under the fifth and sixth series of stock acquisition rights were not exercised because ordinary profit for the fiscal year ending September 2018 fell below the exercise condition of ¥572 million. - FY2018-Q2AdvancedAnnual report
「The stock acquisition rights issued during the second quarter accounting period are as follows.」
The Company actually issued the fourth through sixth series of stock acquisition rights. The fifth and sixth series include conditions under which the exercisable percentage varies according to revenue and ordinary profit, and are granted to directors and employees. - FY2017First statedAnnual report
「At the annual general meeting of shareholders held on 21 December 2017, the Company resolved to grant stock acquisition rights as stock options to the Company’s directors, excluding outside directors, within an annual limit of ¥50,000 thousand, with the aim of increasing their motivation and morale to enhance corporate and shareholder value and promoting management that takes shareholders and the share price into account.」
The Company disclosed for the first time a system for granting stock option compensation of up to ¥50,000 thousand annually to directors other than outside directors.